This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for RUA Life Sciences's Median PS Value or its related term are showing as below:
FRA:AOHA'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23 Med: 0.93 Max: 3.43
Current: 0.3
During the past 13 years, the highest Price to Median PS Value of RUA Life Sciences was 3.43. The lowest was 0.23. And the median was 0.93.
FRA:AOHA's Price-to-Median-PS-Value is ranked better than 85.76% of 316
companies
in the Medical Devices & Instruments industry
Industry Median: 0.8
vs FRA:AOHA: 0.30
RUA Life Sciences Median PS Value Historical Data
The historical data trend for RUA Life Sciences's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of RUA Life Sciences's Median PS Value
For the Medical Devices subindustry, RUA Life Sciences's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RUA Life Sciences's Price-to-Median-PS-Value Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, RUA Life Sciences's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where RUA Life Sciences's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 4.359.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. RUA Life Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €0.078.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RUA Life Sciences (FRA:AOHA) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
RUA Life Sciences's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.102
/
0.34
=
0.30
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RUA Life Sciences Median PS Value Related Terms
Thank you for viewing the detailed overview of RUA Life Sciences's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
RUA Life Sciences PLC is a biomedical polymer technology, components, and medical device company. The company's principal activities comprise exploiting the value of its IP and know-how, medical device contract manufacturing, and development of cardiovascular devices. Its business segments are Royalty and License Income (Biomaterials), Contract Manufacture, Product Development (Vascular), and Product Innovation (Structural Heart). It derives the majority of its revenue from the Contract Manufacture segment. Geographically, it derives the majority of its revenue from the USA and has a presence in Switzerland, Italy, the UK, and Israel.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:AOHA has been successfully added to your 